Our great ideas go nowhere without relationships that bring us the customers, employees and investors we need to succeed.
The co-founder of a new Cincinnati company shares what he learned about pitching, fundraising and claiming small victories.
To be successful as an entrepreneur, have a clear view of next steps. Some people quit a job they don’t like but end up in a new place that’s no better.
Getting off on a bad foot is not fatal for young companies. Serial-entrepreneur Steve Blank explains how a pivot can turn things around.
Don’t let the exhilaration of the initial growth spurt distract you from the fundamentals necessary to grow for years.
The European Central Bank is determined to contain any risks that prolonged low inflation could pose to price stability and economic recovery, policy maker Erkki Liikanen said.
Industries that perform well in the midst of economic uncertainty do just fine in good times, too.
The pros and cons of sole proprietorships, LLCs, S Corps and C Corps.
Starting a company is an endurance race that only a few survive.
When starting a business, often it is just you running the show. Shifting from a ‘solo entrepreneur’ to a founder with a team can be challenging. Here are a few tips to make the process easier.
MetLife said it would resume share repurchases, intending to buy up to $1 billion while it awaits word on whether it will be named a nonbank capital rules.
If you ever need to explain the process of building a new product to your CEO, manager or investor, just look to space travel.
Shipping operators and investors are pouring billions of dollars into building oceangoing crude-oil tankers—taking advantage of low shipbuilding prices and scrambling to get ahead of the unfolding North American energy boom.
Insurance companies in several states are expanding their doctor and hospital networks for less-expensive policies.
RadioShack said its fiscal first-quarter loss widened as the struggling retailer continued to burn through cash and suffer a decline in consumer electronics demand.
Achillion Pharmaceuticals said the U.S. FDA has removed the clinical hold on its experimental hepatitis C treatment, news that adds to the company’s attractiveness as a possible takeover candidate.
Business Equipment Leasing For Business Owners + More ECB Determined to Contain Low Inflation Risk + MORE 06/10/2014
No comments:
Post a Comment